Search
Now showing items 31-40 of 46
Genetics of high risk myeloma
(Institute of Cancer Research (University Of London), 2021-03-31)
Despite significant progress in therapy in the last two decades, the outlook for multiple myeloma (MM) patients is still poor as the disease remains incurable and only 33% of patients survive for up to 10 years after ...
MicroRNAs as biomarkers of response to HER2 inhibitors in gastro-oesophageal cancers
(Institute of Cancer Research (University Of London), 2021-01-31)
Trastuzumab in combination with chemotherapy represents the standard of care in HER2-positive advanced gastro-oesophageal cancer (GOC), but development of resistance limits response. MicroRNAs (miRs) modulate key pathways ...
Targeting androgen receptor splicing in lethal prostate cancer
(Institute of Cancer Research (University Of London), 2021-04-30)
Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...
Roles of cancer associated fibroblasts in squamous cell carcinoma
(Institute of Cancer Research (University Of London), 2021-03-31)
Cancer associated fibroblasts (CAFs) play a key role in the tumour microenvironment (TME) of squamous cell carcinoma. Influenced by cues from cancer cells, CAFS remodel the extracellular matrix and secrete cytokines and ...
Quantitative assessment of patient suitability for magnetic resonance-guided High Intensity Focused Ultrasound Therapy
(Institute of Cancer Research (University Of London), 2021-01-31)
Clinical assessment of a patient's suitability for magnetic resonance-guided high intensity focused ultrasound (MRgHIFU) therapy currently involves subjective judgements based on available diagnostic images and prior ...
Assessment of delivered rectal dose in prostate cancer radiotherapy
(Institute of Cancer Research (University Of London), 2021-11-30)
Prostate radiotherapy gives excellent long-term disease control; however, morbidity from treatment can negatively impact quality of life. To minimise the risk of toxicity a treatment plan is created, which meets dose volume ...
Analysis of novel therapeutic options for adenoid cystic carcinoma of the salivary glands
(Institute of Cancer Research (University Of London), 2021-04-30)
Adenoid cystic adenocarcinoma (ACC) of the salivary glands is characterised by slow growth, frequent metastasis and low survival rates. ACC is resistant to conventional chemotherapy and currently, no systemic agent has ...
Triplet combination of palbociclib, taselisib and fulvestrant and biomarkers for CDK4/6 and PI3-kinase inhibition in breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)
Targeting the commonly upregulated cell-cycle and PI3-kinase pathway in breast cancer are two of the most novel approaches to tackle the disease, with both strategies having led to clinically meaningful results and licensed ...
Biological effects of combination therapy with oncolytic reovirus and palbociclib
(Institute of Cancer Research (University Of London), 2021-09-30)
Reovirus type 3 Dearing (RtD3) is an oncolytic dsRNA virus with limited single-agent activity in clinical studies but has potential for use in combination regimens. Herein, I sought to discover synergistic drug-virotherapy ...
Reference dosimetry of MRI-guided radiotherapy machines
(Institute of Cancer Research (University Of London), 2021-09-30)
A cutting-edge cancer treatment modality, that integrates MRI guidance and delivery of radiotherapy (MRIgRT), sets a new standard for personalised radiotherapy. There are, however, aspects around the accurate determination ...